用克拉迪宾治疗多发性硬化症的实用建议:以色列专家组的观点
Panayiota Petrou1, Anat Achiron2, Esther Ganelin Cohen3
1Hadassah Medical Center, Jerusalem, Israel. petroupanayiota@gmail.com.
Journal of neurology
|July 12, 2023
概括
克拉德里宾片 (Mavenclad) 显示出对复发性复发性多发性硬化症 (MS) 的长期疗效. 这篇文章解决了关于管理多发性硬化症疾病活动和治疗决策的持续问题,这些决策超出了使用克拉德里宾四年的时间.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 2017年 (欧盟) 和2018年 (以色列) 批准的克拉迪片 (Mavenclad) 为高度活跃的复发性复发性多发性硬化症 (MS) 提供高效疗法.
- 现实世界的数据证实了克拉德里宾在启动后至少四年的疗效.
- 对于在克拉迪宾治疗的3-4年和4年之后患有疾病活性的患者的MS管理和治疗决策存在不确定性.
研究的目的:
- 总结有关克拉迪布林治疗困境的现有建议.
- 介绍以色列神经学关键意见领袖对长期使用克拉迪的见解.
- 为了达成对克拉德里宾长期治疗和随访策略的共识.
主要方法:
- 对先前发表的最近建议进行审查.
- 以色列神经病学关键意见领袖的咨询委员会会议于2023年1月29日召开.
- 在多发性硬化症中讨论和达成共识的长期克拉迪管理.
主要成果:
- 现实生活经验支持克拉德里宾在至少四年内持续有效.
- 专家的见解强调,需要在管理疾病活动和治疗决策方面达成共识,超过第四年.
- 以色列主要的论领袖召开会议,讨论和提出基于共识的策略,以长期管理克拉德里宾.
结论:
- 克拉德里宾片在治疗高活性复发性复发性多发性硬化症方面提供了持续的疗效.
- 对于最佳的长期管理策略,需要达成共识,特别是在初始治疗课程后疾病活跃的患者.
- 以色列的临床经验为指导未来的克拉德里宾治疗方案和后续护理提供了宝贵的观点.
相关概念视频
Myasthenia Gravis: Overview and Treatment
1.6K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.6K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
175
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
175
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
198
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
198
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
155
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
155
Alzheimer's Disease: Treatment
219
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
219


